Nomifensine in geriatric inpatients: a placebo-controlled study

Area of Science:

• Geriatric Psychiatry
• Psychopharmacology
• Cognitive Neuroscience

Background:

• Depression is a common and debilitating condition in geriatric populations.
• Cognitive impairment frequently co-occurs with depression in the elderly.
• Effective and safe pharmacological interventions for geriatric depression are needed.

Purpose of the Study:

• To evaluate the efficacy and tolerability of nomifensine in treating depression in geriatric inpatients.
• To assess the impact of nomifensine on cognitive function in this population.

Main Methods:

• A double-blind, randomized, placebo-controlled study.
• 100 geriatric inpatients (average age 75 years) were included.
• Patients were categorized as depressed or non-depressed based on established criteria (Feighner criteria, Hamilton Depression Rating Scale [HDRS]).
• Nomifensine (100 mg daily) was administered and compared to placebo.
• Outcome measures included HDRS scores and various cognitive function tests.

Main Results:

• Nomifensine treatment led to significant improvements in depression scores (HDRS) compared to placebo in depressed geriatric patients, evident early and throughout the treatment period.
• Depressed patients receiving nomifensine demonstrated significant improvements in several cognitive function tests.
• Nomifensine was well tolerated by both depressed and non-depressed geriatric patients.

Conclusions:

• Nomifensine is an effective treatment for depression in geriatric inpatients.
• Nomifensine also positively impacts cognitive function in this patient group.
• The drug exhibits a favorable tolerability profile in the elderly.